Early Implementation of QbD in Biopharmaceutical Development: A Practical Example
暂无分享,去创建一个
Olga Obrezanova | Andreas Arnell | Thomas R. A. Gallagher | J. Zurdo | O. Obrezanova | L. Abrahmsén | C. Ekblad | I. Höidén-Guthenberg | Noel Smith | Jesús Zurdo | Andreas Arnell | T. R. Gallagher | Y. Stallwood | Noel Smith | Ramón Gómez de la Cuesta | Rebecca Michael | Yvette Stallwood | Caroline Ekblad | Lars Abrahmsén | Ingmarie Höidén-Guthenberg | Rebecca C Michael | Ramón Gómez de la Cuesta
[1] I. Macdougall,et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. , 2012, Kidney international.
[2] Marie-Claude Djidja,et al. Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro , 2014, PloS one.
[3] G. Kuchel,et al. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.
[4] Yi Li,et al. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. , 2011, Journal of pharmaceutical sciences.
[5] T. Boone,et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.
[6] Steven J Shire,et al. Formulation and manufacturability of biologics. , 2009, Current opinion in biotechnology.
[7] Khaled Bouri,et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. , 2014, JAMA.
[8] Simona Jevševar,et al. PEGylation of therapeutic proteins , 2010, Biotechnology journal.
[9] A. Beck,et al. Identification of B- and T-Cell Epitopes of BB, a Carrier Protein Derived from the G Protein of Streptococcus Strain G148 , 2003, Clinical Diagnostic Laboratory Immunology.
[10] Olga Obrezanova,et al. Aggregation risk prediction for antibodies and its application to biotherapeutic development , 2015, mAbs.
[11] Fredrik Y Frejd,et al. Half‐Life Extension by Binding to Albumin through an Albumin Binding Domain , 2012 .
[12] David C. Lowe,et al. Application of Biophysics to the Early Developability Assessment of Therapeutic Candidates and Its Application to Enhance Developability Properties , 2013 .
[13] W. Xu,et al. Developability studies before initiation of process development , 2013, mAbs.
[14] M. Pallardy,et al. Primate testing of TGN1412: right target, wrong cell , 2010, British journal of pharmacology.
[15] C. Dobson,et al. Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[16] A. Edmundson,et al. Comparison of the three‐dimensional structures of a humanized and a chimeric Fab of an anti‐γ‐interferon antibody , 1999, Journal of molecular recognition : JMR.
[17] Janet Clarke. Mechanisms of adverse drug reactions to biologics. , 2010, Handbook of experimental pharmacology.
[18] Quynh-Thu Le,et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.
[19] M. Wadhwa,et al. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. , 2011, Journal of immunological methods.
[20] Nicki Panoskaltsis,et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.
[21] G. Gilliland,et al. Structure-based engineering of a monoclonal antibody for improved solubility. , 2010, Protein engineering, design & selection : PEDS.
[22] H. Attarwala,et al. TGN1412: From Discovery to Disaster , 2010, Journal of young pharmacists : JYP.
[23] D. Rudmann,et al. High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins , 2013, Toxicologic pathology.
[24] W. Jiskoot,et al. Erythropoietin-Associated PRCA: Still an Unsolved Mystery , 2006, Journal of immunotoxicology.
[25] T. Igawa,et al. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity , 2013, PloS one.
[26] Vladimir I Razinkov,et al. Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies. , 2012, Journal of pharmaceutical sciences.
[27] Steven Kozlowski,et al. Current and future issues in the manufacturing and development of monoclonal antibodies. , 2006, Advanced drug delivery reviews.
[28] Robert Fischer,et al. Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity , 2011, Pharmaceutical Research.
[29] A. Rosenberg,et al. A risk-based approach to immunogenicity concerns of therapeutic protein product, Pat III , 2004 .
[30] A. Buisman,et al. Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses. , 2013, Journal of immunological methods.
[31] L. Abrahmsén,et al. Engineering of a femtomolar affinity binding protein to human serum albumin. , 2008, Protein engineering, design & selection : PEDS.
[32] Thomas Singer,et al. The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.
[33] R Seitz,et al. Taking immunogenicity assessment of therapeutic proteins to the next level. , 2011, Biologicals : journal of the International Association of Biological Standardization.
[34] Sandeep Kumar,et al. Identification and Impact of Aggregation‐Prone Regions in Proteins and Therapeutic Monoclonal Antibodies , 2010 .
[35] N. Robinson,et al. Molecular clocks. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[36] A. Abuchowski,et al. The clinical efficacy of poly(ethylene glycol)-modified proteins , 1990 .
[37] A. Rathore,et al. Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.
[38] Gary Walsh,et al. Post-translational modifications of protein biopharmaceuticals. , 2009, Drug discovery today.
[39] W. Stemmer,et al. GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model , 2012, PloS one.
[40] P. Parren,et al. Immunogenicity screening in protein drug development , 2007, Expert opinion on biological therapy.
[41] F. Curtin,et al. Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein , 2015, mAbs.
[42] Steven J Shire,et al. Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.
[43] Andrew J Racher,et al. Antibody production. , 2006, Advanced drug delivery reviews.
[44] Jennifer R Litowski,et al. High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. , 2010, Analytical biochemistry.
[45] Fred Jacobson,et al. Protein aggregation and bioprocessing , 2006, The AAPS Journal.
[46] Karsten Mäder,et al. Assessment of net charge and protein-protein interactions of different monoclonal antibodies. , 2011, Journal of pharmaceutical sciences.
[47] S. A. Marshall,et al. Minimizing the immunogenicity of protein therapeutics. , 2004, Drug discovery today.
[48] Noel Smith,et al. Developability Assessment Workflows to De-Risk Biopharmaceutical Development , 2015 .
[49] W. Stemmer,et al. Correction: GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model , 2013, PloS one.
[50] Florian Dismer,et al. 3D structure-based protein retention prediction for ion-exchange chromatography. , 2010, Journal of chromatography. A.
[51] M. Bardor,et al. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins , 2012, Biotechnology journal.
[52] Michele Vendruscolo,et al. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. , 2005, Journal of molecular biology.
[53] Sandeep Kumar,et al. Potential Aggregation-Prone Regions in Complementarity-Determining Regions of Antibodies and Their Contribution Towards Antigen Recognition: A Computational Analysis , 2010, Pharmaceutical Research.
[54] E. Kandel,et al. Proceedings of the National Academy of Sciences of the United States of America. Annual subject and author indexes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[55] J. Zurdo,et al. Developability assessment as an early de-risking tool for biopharmaceutical development , 2013 .
[56] A. D. Nielsen,et al. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[57] S. Singh,et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.
[58] Hongcheng Liu,et al. Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.
[59] William R. Strohl,et al. Therapeutic antibody engineering , 2012 .
[60] Patrick Garidel,et al. Viscosity measurements of antibody solutions by photon correlation spectroscopy: an indirect approach – limitations and applicability for high-concentration liquid protein solutions , 2013, Pharmaceutical development and technology.
[61] A. Rosenberg,et al. Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.
[62] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[63] C. Breneman,et al. Prediction of protein retention in ion-exchange systems using molecular descriptors obtained from crystal structure. , 2001, Analytical chemistry.
[64] Brian M. Murphy,et al. Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.
[65] Deborah S. Goldberg,et al. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. , 2011, Journal of pharmaceutical sciences.
[66] William F Weiss,et al. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.
[67] A. Bircher,et al. Adverse drug reactions to biologics , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[68] M. Ravnborg. [Natalizumab (Tysabri)]. , 2007, Ugeskrift for laeger.
[69] R. Farrell,et al. Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis , 2014 .
[70] L. DeLucas,et al. High-Throughput Self-Interaction Chromatography: Applications in Protein Formulation Prediction , 2009, Pharmaceutical Research.
[71] J. Curling. Affinity chromatography from textile dyes to synthetic ligands by design. Part 2 , 2004 .
[72] M. Kahook,et al. Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis , 2010, The open ophthalmology journal.
[73] A. Rosenberg,et al. A risk-based approach to immunogenicity concerns of therapeutic protein products: Part 2. Considering host-specific and product-specific factors impacting immunogenicity , 2004 .
[74] Michele Vendruscolo,et al. Prediction of aggregation-prone regions in structured proteins. , 2008, Journal of molecular biology.
[75] Bernhardt L Trout,et al. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. , 2012, Journal of pharmaceutical sciences.
[76] Leslie R Evans,et al. Albumin as a versatile platform for drug half-life extension. , 2013, Biochimica et biophysica acta.
[77] D. Grainger. Controlled-release and local delivery of therapeutic antibodies , 2004, Expert opinion on biological therapy.
[78] Tilman Schlothauer,et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies , 2014, mAbs.
[79] D. James,et al. Predicting the expression of recombinant monoclonal antibodies in Chinese hamster ovary cells based on sequence features of the CDR3 domain , 2014, Biotechnology progress.
[80] Quynh-Thu Le,et al. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose , 2008 .
[81] M. Wadhwa,et al. “Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics , 2007, The Journal of Immunology.
[82] S. Joshi,et al. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. , 2011, Journal of pharmaceutical sciences.
[83] Amedeo Caflisch,et al. Computational models for the prediction of polypeptide aggregation propensity. , 2006, Current opinion in chemical biology.
[84] Sandeep Yadav,et al. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. , 2012, Biophysical journal.
[85] A. Serone,et al. Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1 , 2013, Journal of Clinical Immunology.
[86] K. Ishigaki,et al. Cardiopulmonary Arrest After Severe Anaphylactic Reaction to Second Infusion of Infliximab in a Patient with Ankylosing Spondylitis , 2011, The Journal of Rheumatology.
[87] B. Kabakoff,et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.
[88] Herbert J Meiselman,et al. Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.
[89] María Vázquez-Rey,et al. Aggregates in monoclonal antibody manufacturing processes , 2011, Biotechnology and bioengineering.
[90] Michele Vendruscolo,et al. Theoretical approaches to protein aggregation. , 2006, Protein and peptide letters.
[91] Huub Schellekens,et al. Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.
[92] Vibha Jawa,et al. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.
[93] E. Hoffenberg,et al. A Home Infliximab Infusion Program , 2005, Journal of pediatric gastroenterology and nutrition.
[94] H. Mach,et al. High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. , 2012, Therapeutic delivery.
[95] Huijuan Li,et al. Pharmacological significance of glycosylation in therapeutic proteins. , 2009, Current opinion in biotechnology.
[96] J. Arrowsmith,et al. Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.
[97] Bernhardt L Trout,et al. Computational methods to predict therapeutic protein aggregation. , 2012, Methods in molecular biology.
[98] R. Minter,et al. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression , 2013, mAbs.
[99] T. Singer,et al. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies. , 2013, Journal of pharmacological and toxicological methods.
[100] Matthew J. Frigault,et al. Predicting cytokine storms: it's about density. , 2011, Blood.